Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

OBJECTIVES: Bimekizumab selectively neutralises both interleukin (IL)-17A and IL-17F. We report efficacy and safety in a phase IIb dose-ranging study in patients with active ankylosing spondylitis (AS). METHODS: Adults with AS (fulfilling modified New York criteria) were randomised 1:1:1:1:1 to bime...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Gensler, Lianne S, Deodhar, Atul, Baraliakos, Xenofon, Poddubnyy, Denis, Kivitz, Alan, Farmer, Mary Katherine, Baeten, Dominique, Goldammer, Nadine, Coarse, Jason, Oortgiesen, Marga, Dougados, Maxime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213320/
https://www.ncbi.nlm.nih.gov/pubmed/32253184
http://dx.doi.org/10.1136/annrheumdis-2020-216980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213320/
https://www.ncbi.nlm.nih.gov/pubmed/32253184
http://dx.doi.org/10.1136/annrheumdis-2020-216980

Ejemplares similares